BCL2L1 and glioblastoma: Recent drug screening in a GBM model with MN1::PATZ1 fusion identified promising candidates: paclitaxel, D-actinomycin, volasertib (PLK1 inhibitor), navitoclax (BCL-2/BCL-XL/BCL-W inhibitor), and I-BET-151 (bromodomain inhibitor) (25, 26).